Invent.
Collaborate.
Protect.

Laura Arneson, Ph.D.

Phone:

Disclaimer: Transmission of information to us via voicemail or this website does not establish an attorney-client relationship. If you are not already a client of Mueting Raasch Group, do not send any information that you would have treated confidentially.

Biography

Laura is a patent attorney practicing in the areas of biotechnology and the biomedical sciences. Before attending law school, Laura was a post-doctoral fellow for Mayo Clinic's technology transfer office. Prior to joining Mueting Raasch Group, she clerked for the Honorable John R. Tunheim of the U.S. District Court of the District of Minnesota. In her free time, Laura enjoys biking, reading novels, knitting, and baking.

Education

  • University of Minnesota Law School
    • J.D.
    • Honors: magna cum laude, Order of the Coif
    • Minnesota Law Review, Lead Note and Comment Editor
  • Mayo Graduate School
    • Ph.D., Immunology
    • National Science Foundation (NSF) Fellow
  • St. Olaf College
    • B.A., Biology & Mathematics
    • Honors: summa cum laude

Bar Admissions

  • Minnesota
  • U.S. District Court, District of Minnesota
  • U.S. Patent and Trademark Office

Professional Associations

  • American Intellectual Property Law Association (AIPLA), Biotechnology Committee, Co-Chair Subject Matter Eligibility Subcommittee
  • Minnesota Women Lawyers, Publications Committee, Co-Chair
  • Minnesota Intellectual Property Law Association
  • Graduate Women in Science, National Membership Secretary, 2015-2016, Xi Chapter, Board Member, 2013-2018

Publications & Presentations

  • Laura N. Arneson, presentation and paper, Revisiting § 102 after Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc.: An Update on Caselaw and Real-World Issues of Prior Art Including Public Use and Sale, AIPLA Spring Meeting, May 2020 (virtual)
  • Laura N. Arneson, presentation, Restriction Elections & Double Patenting, AIPLA Patent Prosecution Boot Camp, February 2020 (Seattle, Washington)
  • Laura N. Arneson, In Case You Missed It: A Round Up of Recent Subject Matter Eligibility Decisions and Articles), AIPLA Biotech Buzz, October 2020
  • Christopher Thomas, Allison Dobson, Charles W. Calkin, Laura N. Arneson, The Federal Circuit Provides a Glimmer of Hope for the Patent Eligibility of Method Claims Involving Natural Phenomena, AIPLA Biotech Buzz, April 2020
  • Laura Arneson, Summary of USPTO February 2019 Revised Patent Subject Matter Eligibility Guidance and Other Materials, AIPLA Biotech Buzz, March 2019
  • Laura N. Arneson, Jennifer Wichelman, We Are MWL: Past Present and Future (Introduction to This Issue of With Equal Right), With Equal Right (Journal of Minnesota Women Lawyers), Winter 2018
  • Laura N. Arneson, Advocating for the Many, Instead of the Few: An Interview with Caroline Fredrickson, With Equal Right (Journal of Minnesota Women Lawyers), Fall 2015
  • Laura N. Arneson, Defining Unpatented Article: Why Labeling Products with Expired Patent Numbers Should Not Be False Marking, 95 MINN. L. REV. 650 (2010).
  • Arneson LN, Segovis CM, Gomez TS, Schoon RA, Dick CJ, Lou Z, Billadeau DD, Leibson PJ. 2008. Dynamin 2 regulates granule exocytosis during NK cell-mediated cytotoxicity. J Immunol. 181(10):6995–7001.
  • Arneson LN, Brickshawana A, Segovis CM, Schoon RA, Dick CJ, Leibson PJ. 2007. Cutting edge: Syntaxin 11 regulates lymphocyte-mediated secretion and cytotoxicity. J Immunol. 179(6):3397–401.
  • Khurana D, Arneson LN, Schoon RA, Dick CJ, Leibson PJ. 2007. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. J Immunol. 178(6):3575–82.
  • Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. 2006. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol. 7(5):524–32. Epub 2006 Apr 2.
  • Arneson LN and Leibson PJ. 2005. Signaling in natural immunity: Natural killer cells. In: Neuromimmune Biology, Vol. 5: Natural immunity, pp. 151–166, eds. Lóránd Bertók and Donna Chow; Elsevier, Amsterdam.

Technologies

  • Biochemistry
  • Biomedical sciences
  • Biotechnology
  • Cancer biology
  • Chemical technology
  • Genetics
  • Immunology
  • Molecular biology
  • Nucleic acids and sequencing
  • Paper and filter media
  • Pharmaceuticals
  • Polymers and coatings
  • Protein expression
  • Small molecules

Services

  • Domestic and International Patent Prosecution
  • Clearance and Opinions